CHK-336
外观
| CHK-336 | |
|---|---|
| 首选IUPAC名 2-[5-(cyclopropylmethyl)-3-(4-fluorophenyl)-4-[(3-fluoro-4-sulfamoylphenyl)methyl]pyrazol-1-yl]-1,3-thiazole-4-carboxylic acid | |
| 识别 | |
| CAS号 | 2743436-86-2 |
| PubChem | 162358463 |
| ChemSpider | 129432022 |
| SMILES |
|
| 性质 | |
| 化学式 | C24H20F2N4O4S2 |
| 摩尔质量 | 530.57 g·mol−1 |
| 若非注明,所有数据均出自标准状态(25 ℃,100 kPa)下。 | |
CHK-336是一种含氟有机硫化合物,分子式C
24H
20F
2N
4O
4S
2,可作为乳酸脱氢酶的小分子抑制剂,由诺华集团旗下的Chinook Therapeutics研发,用于治疗高草酸尿症[1]。
参考文献
[编辑]- ^ Cox, Jennifer H.; Boily, Marc-Olivier; Caron, Alex; Chefson, Amandine; Chong, Oliver; Ding, Jim; Dumais, Valerie; Gaudreault, Samuel; Gomez, Robert; Guthrie, James; Holmes, Ross P.; King, Andrew J.; Knight, John; Lester, Jeff; Lowther, W. T. Discovery of CHK-336: A First-in-Class, Liver-Targeted, Small Molecule Inhibitor of Lactate Dehydrogenase for the Treatment of Primary Hyperoxaluria: PO1620
. Journal of the American Society of Nephrology. October 2020, 31 (10S): 514. ISSN 1046-6673. doi:10.1681/ASN.20203110S1514a (英语).